Skip Navigation

Saleh Alqahtani, M.B.Ch.B., M.S.

Saleh Ali Alqahtani, M.B.Ch.B., M.S.

Headshot of Saleh Alqahtani

Languages: English, Arabic


Cirrhosis, Colon Polyps, Colonoscopy, Digestive Disorders, Endoscopy, Fatty Liver, Gastroenterology, Gastroesophageal Reflux Disease (GERD), Gastrointestinal Bleeding, Hepatitis B (HBV), Hepatitis C (HCV), Indigestion, Liver Cancer, Liver Fibrosis, Liver Transplant, Pancreatic and Biliary Disease more

Research Interests

Drug Induced Liver Injury; Liver Cancer; Hepatitis B; Hepatitis C; Fatty Liver Disease more


Dr. Saleh Alqahtani is highly regarded expert in liver and digestive diseases, endoscopy, and liver transplant, Dr. Alqahtani has been the principal investigator for clinical trials related to the management of fatty liver disease and viral hepatitis including novel agents. He also is the co-investigator for numerous clinical trials in liver cancer, liver cirrhosis, and outcome of liver transplantation.

The recipient of several awards and honors, Dr. Alqahtani has been an invited speaker both nationally and internationally, lecturing in Latin America, Asia, and Europe and has authored many publications and book chapters. Board Certified in transplant hepatology, gastroenterology, and internal medicine, Dr. Alqahtani is a member of professional societies including the American College of Gastroenterology, the Mayo Clinic Alumni Association, the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver, and The Johns Hopkins Medical & Surgical Association.

Before coming to Johns Hopkins, Dr. Alqahtani served as Associate Director of the Gastroenterology Fellowship Program at the University of Texas Southwestern Medical Center in Dallas, Texas.  He also was an Instructor in Medicine at the Mayo Clinic in Rochester, Minnesota.

Dr. Alqahtani earned his medical degree at King Abdulaziz University in Saudi Arabia, completed an internal medicine residency program at University of Western, performed a gastroenterology fellowship at the University of Calgary, and completed an advanced liver diseases and liver transplantation fellowship at the Mayo Clinic, Rochester, Minnesota. more

Departments / Divisions

  • Medicine at Sibley Memorial Hospital

Centers & Institutes



  • MBChB MS; King Abdul Aziz University (1999)


  • Internal Medicine; University of Western Ontario Schulich School of Medicine & Dentistry (2004)


  • Mayo Clinic College of Medicine & Science (2008)
  • Gastroenterology; University of Calgary (2007)

Board Certifications

  • American Board of Internal Medicine (Gastroenterology) (2007)
  • American Board of Internal Medicine (Internal Medicine) (2004)

Research & Publications

Clinical Trial Keywords

Hepatitis C, Fatty Liver, Liver Cancer, Liver Transplant

Clinical Trials

Fatty Liver, Hepatitis C, Hepatitis B, Liver cancer, Liver transplant, Liver failure, Cirrhosis

Selected Publications

Alqahtani SA, Kleiner DE, Ghabril M, Gu J, Hoofnagle JH, Rockey DC; DILIN study investigators, Identification and Characterization of Cefazolin-induced Liver Injury. Clin Gastroenterol Hepatol. 2015 Jul;13(7):1328-1336.e2

Alqahtani SA, Afdhal N2, Zeuzem S, Gordon SC, Mangia A, Kwo P, Fried M, Yang JC, Ding X, Pang PS, McHutchison JG, Pound D, Reddy KR, Marcellin P, Kowdley KV, Sulkowski M.  Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. Hepatology. 2015 Jul;62(1):25-30. doi: 10.1002/hep.27890. Epub 2015 Jun 1

Alqahtani S, Ozaras R, Isakov V, Wyles D, Ferenci P, Feld JJ, Calinas F, Gschwantler M, Gane E, Crawford D, Jacobson IM, Dumas EO, King M, Sulkowski.  Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin.  J Viral Hepat. 2017 Apr;24(4):280-286. doi: 10.1111/jvh.12641. Epub 2016 Dec 9.

Welzel TM, Nelson DR, Morelli G, Di Bisceglie A, Reddy RK, Kuo A, Lim JK, Darling J, Pockros P, Galati JS, Frazier LM, Alqahtani S,Sulkowski MS, Vainorius M, Akushevich L, Fried MW, Zeuzem S; HCV-TARGET Study Group.  Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.  Gut. 2017 Oct;66(10):1844-1852. doi: 10.1136/gutjnl-2016-311609. Epub 2016 Jul 13.

Alqahtani SA, Larson AM.  Adult liver transplantation in the USA.  Curr Opin Gastroenterol. 2011 May;27(3):240-7. doi: 10.1097/MOG.0b013e3283457d5d.

Alqahtani S, Sulkowski M.  Current and Evolving Treatments of Genotype 1 Hepatitis C Virus.  Gastroenterol Clin North Am. 2015 Dec;44(4):825-43. doi: 10.1016/j.gtc.2015.06.001. Epub 2015 Aug 11

Contact for Research Inquiries

720 Rutland Avenue
Ross Building, Suite 918
Baltimore, MD 21205 map

Videos & Media

Recent News Articles and Media Coverage

Hep C Combo Pill May Cure Those Who Can Afford It, WebMD (2014) 

5 Reasons You May Be at Risk for Liver Diseases, Johns Hopkins Medicine

5 Ways to Be Kind to Your Liver. Johns Hopkins Medicine

Is this you? Edit Profile
back to top button